A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma
Study of Armodafinil (Nuvigil) to Reduce Cancer-Related Fatigue in Patients with High-Grade Glioma (HGG)
Sponsor: Alliance for Clinical Trials in Oncology
Enrolling: Male and Female Patients
IRB Number: AAAR9176
U.S. Govt. ID: NCT01781468
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to: See if taking the study agent, armodafinil, at a dose of 150mg or 250mg, will improve problems with fatigue in patients who have been diagnosed with cancer and are experiencing fatigue. See the effects (good and bad) of taking Armodafinil compared to placebo (an inactive agent) on cancer-related fatigue
This study is closed
Mary Welch, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with a glioblastoma or gliosarcoma? Yes No
Have you undergone surgery (gross total or subtotal resection) or biopsy? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator